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Introduction
============

Esophageal cancer (EC) is one of the most common cancers diagnosed, with an estimated global incidence of 455,800 \[[@REF1]\]. In the United States, it is estimated that there will be 17,290 new cases and 15,850 deaths in 2018 \[[@REF2]\]. In addition to the rise in incidence over the past few decades \[[@REF3]\], there appears to be a concurrent change in histological type, with studies reporting a 463% increase in the incidence of adenocarcinoma (AC) in Americans in 2000-2004 as compared to 1975-1979 \[[@REF4]\]. Adenocarcinoma has replaced squamous cell carcinoma (SCC) as the most common type of esophageal carcinoma, in part due to an increase in risk factors for AC such as obesity and gastroesophageal reflux disease (GERD) \[[@REF5]\]. The tumor biology of EC is still not fully understood, and patients with SCC have been shown to have significantly poorer survival than patients with AC \[[@REF6]\]. Efforts at elucidating the underlying mechanisms as well as developing biomarkers for early detection and screening have proved daunting \[[@REF7]\]. Moreover, there seems to be a racial disparity in survival between white and black patients with esophageal carcinoma for reasons that are still not fully clear, with the age-adjusted incidence and death for blacks almost twice that for whites \[[@REF8]\].

This study uniquely analyzes symptoms and risk factors at presentation as well as various demographic, pathological, clinical, and laboratory variables. In addition to delineating trends in the presentation and treatment of esophageal cancer patients in an American cohort, it seeks to closely examine the impact of race and histology on survival in our veteran patient population.

Materials and methods
=====================

The variables assessed in the study are shown in Table [1](#TAB1){ref-type="table"}.

###### Variables Included in the Study

EMR: endoscopic mucosal resection; BMI: body mass index; WBC: white blood cell; ECOG: Eastern Cooperative Oncology Group

  ----------------------- ---------------------- ------------------------------- --------------------------------- ----------------------------------- ---------------------------
  Demographic Variables   Laboratory Values      Clinical Variables              Symptoms at Presentation          Risk Factors                        Treatment
  Age                     Albumin at Diagnosis   Survival Days                   Hoarseness                        History of Alcohol Use              Surgery
  Race                    WBC at Diagnosis       Age at Diagnosis                Fatigue                           History of Tobacco Use              EMR
  Gender                                         Stage at Diagnosis              Regurgitation                     History of GERD Symptoms            Postop Adjuvant Therapy
  BMI at Diagnosis                               ECOG Functional Status          Weight loss                       History of H pylori                 Neoadjuvant Therapy
                                                 Histological Type               Chest pain                        On PPI at time of Diagnosis         Definitive Chemoradiation
                                                 Anatomical Location of Cancer   Dysphagia to solids               History of Cholecystectomy          Stent Placement
                                                                                 Dysphagia to solids and liquids   Prior Gastrectomy                    Gastric/Jejunal Tube
                                                                                 Heart Burn                        History of Atrophic gastritis       Palliative Therapy
                                                                                 Nausea/Vomiting                   History of Head/Neck Cancer         Any Chemoradiation
                                                                                 Hematemesis                       Family History                       
                                                                                 Hematochezia/Melena               History of Achalasia                 
                                                                                 Anemia                            History of Esophagogastric Cancer    
                                                                                 Abdominal Pain                                                         
                                                                                 Odynophagia                                                            
                                                                                 Neck mass                                                              
                                                                                 Abdominal mass                                                         
                                                                                 Neurological symptoms                                                  
  ----------------------- ---------------------- ------------------------------- --------------------------------- ----------------------------------- ---------------------------

Survival was calculated based on the date of pathological diagnosis obtained from pathology records and the date of demise and, where unavailable, a cutoff date of September 01, 2013 was used. Presenting complaints and risk factors were abstracted from the medical provider notes on the patient's computerized charts. Laboratory values and demographic values were obtained on the date closest to pathological diagnosis durin­g that hospital admission. Eastern Cooperative Oncology Group (ECOG) scores and treatment regimen were abstracted from the oncology notes and the location of cancer from the endoscopy notes. The location of the cancer was obtained from the endoscopy notes, and a value of 30 cm from the incisors was used as the demarcation point between upper and lower tumors. The association between each clinical, demographic, and laboratory factor between subgroups was evaluated by Fisher's exact test or the chi-square test for categorical variables, and by the two sample t-tests for continuous variables. Survival was calculated using Kaplan-Meier curves, and survival between groups was compared using the log-rank test. All analyses were performed using SPSS (IBM, Armonk, New York, United States). Statistical significance was determined at p ≤ .05. A p-value of \<0.1 was considered marginally significant. This study was approved by the Institutional Review Board (IRB) at our institution.

Results
=======

Demographics and epidemiology

A total of 122 patients with esophageal cancer were identified. Their features are presented in Table [2](#TAB2){ref-type="table"}. 

###### Demographics

BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; EMR: endoscopic mucosal resection; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor; SEM: standard error of the mean; WBC: white blood cell

  ---------------------------------- ------------- ---------------------------------- -------------
                                     n (SEM/%)                                        n (SEM/%)
  Mean Age at Diagnosis (years)      64.0 (0.9)    Interventions                       
  Mean Age at Demise (years)         65.1 (1.0)    Surgery                            19 (16%)
  Sex                                              EMR                                7 (6%)
  Male                               119 (97.5%)   Postop Adjuvant Therapy            2 (2%)
  Female                             3 (2.5%)      Neoadjuvant Therapy                25 (20.5%)
  Race                                             Definitive Chemoradiation          25 (20.5%)
  White                              92 (75.4%)    Stent Placement                    26 (21.3%)
  Black                              25 (20.5%)    Gastric/Jejunal Tube               51 (41.8%)
  Hispanic                           4 (3.3%)      Palliative therapy                 39 (32%)
  Unknown                            1 (0.8%)      Risk Factors                        
  Mean Weight Diagnosis (lbs)        178.3 (4.6)   Alcohol                            90 (73.8%)
  Mean BMI Diagnosis                 26.0 (0.7)    Tobacco                            101 (82.8%)
  Mean Albumin at Diagnosis (g/dl)   3.6 (0.06)    GERD                               53 (43.4%)
  Mean WBC at Diagnosis (K/µL)       8.7 (0.3)     H pylori                           5 (4.1%)
  Histology                                        On PPI                             35 (28.7%)
  Adenocarcinoma                     75 (61.5%)    Cholecystectomy                    11 (9.0%)
  Squamous Cell Carcinoma            41 (33.6%)    Prior gastrectomy                  0
  Undifferentiated                   6 (4.9%)      Atrophic gastritis                 0
  Location                                         Head/Neck cancer                   4 (3.3%)
  Upper                              32 (26.2%)    Family history Esophageal cancer   7 (5.7%)
  Lower                              90 (73.8%)    Achalasia                          3 (2.5%)
  Stage at Diagnosis                               Prior Esophageal/Gastric cancer    4 (3.3%)
   I                                 18 (14.8%)    Symptoms at Presentation            
   II                                19 (15.6%)    Hoarseness                         8 (6.6%)
   III                               26 (21.3%)    Fatigue                            17 (13.9%)
   IV                                50 (41.0%)    Regurgitation                      22 (18%)
   Unknown                           9 (7.4%)      Weight loss                        68 (55.7%)
  ECOG at Diagnosis                                Chest pain                         14 (11.5%)
  0                                  23 (18.9%)    Dysphagia to solids                49 (40.2%)
  1                                  39 (32.0%)    Dysphagia to solids & liquids      37 (30.3%)
  2                                  19 (15.6%)    Heart burn                         21 (17.2%)
  3                                  17 (13.9%)    Nausea/Vomiting                    12 (9.8%)
  4                                  3 (2.5%)      Hematemesis                        8 (6.6%)
  Unknown                            21 (17.2%)    Hematochezia/Melena                12 (9.8%)
  Survival ( days)                                 Anemia                             7 (5.7%)
  Mean                               591 ±(76 )    Abdominal pain                     9 (7.4%)
  Median                             253± (28 )    Odynophagia                        14 (11.5%)
                                                   Neck mass                          1 (0.8%)
                                                   Abdominal mass                     1 (0.8%)
                                                   Neurological symptoms              1 (0.8%)
  ---------------------------------- ------------- ---------------------------------- -------------

The mean age was 64 ± 0.9 years and the mean body mass index (BMI) at diagnosis was 26 ± 0.7. The cohort was predominantly male (97.5%) and white (75.4%). AC was found in 61.5% of the patients and 33.6% had SCC. The majority of the cancers were in the lower esophagus (73.8%) as compared to the upper esophagus (26.2%).

The patients presented mostly with advanced stage carcinoma with almost half (41%) presenting with metastatic disease. The vast majority of patients had a documented history of tobacco (82.8%) and alcohol (73.8%) use. A significant number also had gastroesophageal reflux disease (GERD) (43.4%), whereas only 28.7% were on a proton pump inhibitor. The most common complaint at presentation was weight loss (55.7%) followed by dysphagia to solids (40.2%). In terms of interventions, 41.8% patients received a gastric or jejunal feeding tube, 21.3% received esophageal stents, 15.6% patients had an esophagectomy, and 66.4% patients received some form of chemotherapy or radiation.

Survival

On a Kaplan-Meier analysis, overall median survival for the entire cohort was 253 ± 28 days. 

Histology

When the cohort was stratified by histology, patients with AC had longer median survival than those with SCC (303 ± 48 days vs. 233 ± 24, 95% CI 197-339, p=0.01). In patients with potentially resectable cancer (Stage I-III), SCC patients had significantly poorer survival than AC (333 ± 58 vs. 638 ± 152 days, 95% CI 306-634, p=0.006)

Race

When only black and white patients were compared, whites had a longer median survival (254 ± 39 vs. 193 ± 65 days, 95% CI 205-295, p=0.07). However, when black and whites with potentially resectable cancers (Stage I-III) were compared, there was a statistically significant difference in survival between whites and blacks (538 ± 202 vs. 253 ± 46 days, 95% CI 269-603, p=0.03).

Stage

As expected, there was an inverse relationship between stage of disease at presentation and survival with a median survival of 1447 ± 651 days, 402 ± 137 days, 292 ± 53 days, and 134 ± 35 days for Stage I, II, III, and IV patients, respectively (95% CI 199-307, p\<0.0001).

Resectability

Patient survival was stratified by resectability. Stage IV patients were considered to have nonresectable tumors (NR). Patients that had potentially resectable disease (defined as Stage I-III) were grouped into patients that received an esophagectomy (R+SURG), endoscopic mucosal resection (R+EMR), and patients that did not receive surgical/endoscopic intervention (R-). Patients with an unknown stage were not included in the analysis. Patients with NR cancer had poorer survival compared to patients with resectable cancer (stage I-III) (134 ± 45 vs. 470 ± 84 days, 95% CI 193-343, p\<0.0001).

There was a clinically and statistically significant difference in survival between the NR (stage IV) group (134 ± 35 days) and resectable (I-III) groups (R-:364 ± 81 days, R+SURG: 733 ± 342 days, R+EMR: 2212 ± 625 days, p\<0.0001).

 Among the group that was potentially resectable (stages I-III), the median survival for R- patients compared with patients who received any kind of surgical/endoscopic intervention (R+Surg and R+EMR) was 364 ± 81 days vs. 1044 ± 278 days (95% CI 193-343, p\<0.0001).

This data is represented in Figure [1](#FIG1){ref-type="fig"}.
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Univariate analysis

By Race

A univariate analysis was conducted to elucidate any differences in any of the measured variables between white and black patients (Table [3](#TAB3){ref-type="table"}).

###### Univariate Analysis by Race

\* mean (+SEM); BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; EMR: endoscopic mucosal resection; GERD: gastroesophageal reflux disease; SEM: Standard error of the mean; WBC: white blood cells

  ----------------------------------- -------------- ----- -------------- ----- ----------
                                      White (n=92)   \%    Black (n=25)   \%    p-value
  Demographics & Clinical Variables                                              
  Adenocarcinoma (AC)                 70             76%   3              12%   \<0.0001
  Squamous Cell Carcinoma (SCC)       18             20%   20             80%    
  Upper Esophagus                     21             23%   10             40%   0.08
  Lower Esophagus                     71             77%   15             60%    
  Hypoalbuminemia                     31             34%   8              32%   0.9
  WBC\*                               9.0+0.4        .     7.5+0.5        .     0.6
  Albumin \*                          3.64+0.07      .     3.46+0.1       .     0.2
  Age\*                               64.4+1.1       .     63.6+2         .     0.7
  BMI\*                               26.42+0.8      .     23.5+1.3       .     0.8
  ECOG\*                              1.38+0.12      .     1.48+0.25      .     0.7
  Stage I                             13             14%   3              12%   0.6
  Stage II                            16             17%   2              8%    .
  Stage III                           18             20%   7              28%   .
  Stage IV                            39             42%   10             40%   .
  Interventions                                                                  
  Surgery                             17             18%   1              4%    0.1
  EMR                                 5              5%    2              8%    0.6
  Postop Adjuvant Therapy             1              1%    0              0%    0.8
  Neoadjuvant Therapy                 20             22%   5              20%   0.9
  Definitive Chemoradiation           19             21%   6              24%   0.7
  Stent Placement                     19             21%   7              28%   0.4
  Gastric/Jejunal Tube                40             43%   10             40%   0.8
  Palliative therapy                  29             32%   9              36%   0.7
  Any Chemo/Rad                       62             67%   17             68%   1.0
  Risk Factors                                                                   
  Alcohol                             69             75%   18             72%   0.8
  Tobacco                             79             86%   20             80%   0.5
  GERD                                40             43%   10             40%   0.8
  H pylori                            4              4%    1              4%    0.7
  On Proton Pump Inhibitor            24             26%   8              32%   0.6
  Cholecystectomy                     8              9%    2              8%    0.6
  Prior Gastrectomy                   0              0%    0              0%    .
  Atrophic Gastritis                  0              0%    0              0%    .
  Head/Neck Cancer                    3              3%    1              4%    0.6
  Family History Esophageal Cancer    6              7%    1              4%    0.5
  Achalasia                           2              2%    1              4%    0.5
  Prior Esophageal/Gastric Cancer     2              2%    1              4%    0.5
  Symptoms at Presentation                                                       
  Hoarseness                          7              8%    1              4%    0.5
  Fatigue                             16             17%   1              4%    0.1
  Regurgitation                       16             17%   6              24%   0.5
  Weight Loss                         51             55%   16             64%   0.4
  Chest Pain                          10             11%   4              16%   0.5
  Dysphagia to Solids                 32             35%   16             64%   0.008
  Dysphagia to Solids and Liquids     32             35%   4              16%   0.1
  Heart Burn                          17             18%   3              12%   0.5
  Nausea/Vomiting                     9              10%   2              8%    0.6
  Hematemesis                         5              5%    2              8%    0.6
  Hematochezia/Melena                 7              8%    4              16%   0.2
  Anemia                              6              7%    0              0%    0.3
  Abdominal Pain                      8              9%    0              0%    0.2
  Odynophagia                         9              10%   5              20%   0.2
  Neck Mass                           0              0%    1              4%    0.2
  Abdominal Mass                      0              0%    1              4%    0.2
  Neurological Symptoms               1              1%    0              0%    0.8
  ----------------------------------- -------------- ----- -------------- ----- ----------

Hispanic patients were excluded due to low sample size. There were similar rates of smoking (86% vs. 80%, p=0.47) and alcohol use (75% vs. 72%, p=0.8) between whites and blacks. The majority of white patients presented with AC compared to black patients (76% vs. 12%, p\<0.0001), whereas black patients were more likely to present with SCC compared to whites (80% vs. 20%, p\<0.0001). Black patients with SCC compared to white patients with SCC had similar rates of alcohol (80% vs. 83%) and tobacco use (80% vs. 100%). There was no significant difference in the stage of presentation at diagnosis between races, with 62% of white patients presenting with advanced stage disease (III+IV) compared to 68% of black patients. A higher percentage of white patients received surgery compared to black patients (18% vs. 4%, p=0.1). Among patients with potentially resectable cancer, whites again received surgery more often than blacks (36% vs. 8%, p=0.08). Out of all variables assessed, only histology (AC: 12% black vs. 76% white, p\<0.0001) and dysphagia to solids (64% black vs. 35% white, p=0.008) proved to be statistically significant between whites and blacks.

By Histology

A univariate analysis was conducted to elucidate any differences in any of the measured variables between patients with differing histological subtypes (Table [4](#TAB4){ref-type="table"}).

###### Univariate Analysis by Histology

\* mean (+SEM); BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; EMR: endoscopic mucosal resection; GERD: gastroesophageal reflux disease; SEM: standard error of the mean; WBC: white blood cell

  ---------------------------------- ------------ ----- ------------ ----- ----------
                                     AC (n=75)    \%    SCC (n=41)   \%    p value
  Demographic & Clinical Variables                                          
  White                              70           93%   18           44%   \<0.0001
  Black                              3            4%    20           49%   .
  Upper Esophagus                    6            8%    24           59%   \<0.0001
  Lower Esophagus                    69           92%   17           41%   .
  Hypoalbuminemia                    23           31%   16           39%   0.4
  WBC \*                             8.5+0.3      .     8.91+4.6     .     0.6
  Albumin \*                         3.7+0.1      .     3.4+0.1      .     0.3
  Age\*                              64.2+1.2     .     65.0+1.7     .     0.7
  BMI\*                              27.7+ 0.9    .     23.0 + 0.9   .     0.002
  ECOG\*                             1.27 + 0.1   .     1.57+ 0.2    .     0.2
  Stage I                            13           17%   5            12%   0.2
  Stage II                           15           20%   4            10%   .
  Stage III                          13           17%   13           32%   .
  Stage IV                           31           41%   13           32%   .
  Interventions                                                             
  Surgery                            16           21%   3            7%    0.07
  EMR                                5            7%    2            5%    0.5
  Postop Adjuvant Therapy            2            3%    0            0%    0.5
  Neoadjuvant Therapy                15           20%   9            22%   0.8
  Definitive Chemoradiation          15           20%   10           24%   0.6
  Stent Placement                    12           16%   11           27%   0.1
  Gastric/Jejunal Tube               30           40%   17           41%   0.9
  Palliative Therapy                 26           35%   9            22%   0.1
  Any Chemo/Rad                      52           69%   24           59%   0.2
  Risk Factors                                                              
  Alcohol                            53           71%   33           80%   0.2
  Tobacco                            62           83%   36           88%   0.5
  GERD                               35           47%   15           37%   0.3
  H pylori                           3            4%    2            5%    0.8
  On Proton Pump Inhibitor           23           31%   10           24%   0.5
  Cholecystectomy                    9            12%   1            2%    0.1
  Prior Gastrectomy                  0            0%    0            0%    .
  Atrophic Gastritis                 0            0%    0            0%    .
  Head/Neck Cancer                   2            3%    2            5%    0.6
  Family History Esophageal Cancer   6            8%    1            2%    0.4
  Achalasia                          0            0%    3            7%    0.04
  Prior Esophageal/Gastric Cancer    3            4%    1            2%    0.6
  Symptoms at Presentation                                                  
  Hoarseness                         1            1%    6            15%   0.008
  Fatigue                            15           20%   2            5%    0.03
  Regurgitation                      14           19%   8            20%   0.9
  Weight Loss                        38           51%   26           63%   0.2
  Chest Pain                         8            11%   4            10%   0.6
  Dysphagia to Solids                24           32%   22           54%   0.02
  Dysphagia to Solids and Liquids    23           31%   13           32%   0.9
  Heart Burn                         14           19%   5            12%   0.4
  Nausea/Vomiting                    10           13%   2            5%    0.2
  Hematemesis                        6            8%    2            5%    0.7
  Hematochezia/Melena                7            9%    5            12%   0.6
  Anemia                             5            7%    2            5%    0.5
  Abdominal Pain                     8            11%   1            2%    0.2
  Odynophagia                        6            8%    6            15%   0.3
  Neck Mass                          0            0%    1            2%    0.4
  Abdominal Mass                     1            1%    0            0%    0.6
  Neurological Symptoms              1            1%    0            0%    0.6
  ---------------------------------- ------------ ----- ------------ ----- ----------

Both smoking (83% vs. 88%, p=0.5) and alcohol use (71% vs. 80%, p=0.2) were equally prevalent in both the AC and SCC groups. There were fewer patients overall with SCC who underwent surgery compared with AC (7% vs. 21%, p=0.07). When looking at patients with potentially resectable cancers, fewer patients in the SCC group received surgery compared with the AC group (14% vs. 45%, p=0.02). There was no significant difference in interventions such as chemotherapy, radiation, enteral tube feeding, or esophageal stenting between AC and SCC patients (see Table [4](#TAB4){ref-type="table"}).

Of the patients in our cohort who had a history of achalasia, all presented had SCC. More patients with SCC complained of dysphagia to solids (p=0.02) and hoarseness (p=0.008) whereas more patients with AC presented complaining of fatigue (p=0.03). Patients with AC had a higher BMI at presentation compared with SCC (27.7+ 0.9 vs. 23.0 + 0.9, p=0.002).

Multivariable analysis

All variables with a univariate analysis p-value \< 0.1 obtained on a comparison between the histology and race subgroups were included in a multivariable Cox regression analysis to elucidate predictors of mortality (Table [5](#TAB5){ref-type="table"}).

###### Variables Included in the Multivariate Model

  --------------------------------- --------------------
  Variables                         Univariate p value
  Race                              \<0.0001
  Surgery                           0.07
  Histology                         \<0.0001
  Anatomic Location                 \<0.0001
  History of Achalasia              0.04
  History of Cholecystectomy        0.1
  Hoarseness                        0.008
  Fatigue                           0.03
  Dysphagia to Solids and Liquids   0.02
  --------------------------------- --------------------

Of the variables included, only surgery (p=0.001) was statistically significant.

Discussion
==========

Although there was a higher percentage of SCC in blacks as well as a poorer survival rate for SCC compared with AC, the multivariable analysis revealed that histology and race did not play a role in overall survival. The receipt of an esophagectomy was an independent predictor of survival.

Esophagectomy for locally advanced esophageal cancer is currently the standard of care, and neoadjuvant chemoradiation has been shown in several studies to confer a survival advantage \[[@REF8]-[@REF10]\]. Definitive chemoradiation alone has generally not been recommended, although a recent Cochrane meta-analysis suggested that survival outcomes for definitive chemoradiation may be equal to surgery in SCC patients \[[@REF11]\]. Several studies have suggested that surgical resection for esophageal cancer is underused \[[@REF12]\], likely due to a combination of factors, including limited access to high-volume centers and patient reluctance to undergo surgery.

In our study, on a Kaplan-Meier analysis, there was a statistically and clinically apparent survival benefit of receiving an esophagectomy (p\<0.0001). However, in our cohort, there was a total of 52% patients that had potentially resectable tumors (R+ surgery/EMR), but less than half of them (41%) underwent resection. When analyzing causes for not receiving surgery in potentially resectable patients (R-) (Table [6](#TAB6){ref-type="table"}), 16% of the patients were found to have cancer that advanced after neoadjuvant treatment that precluded them from surgery. Almost one-third of the patients (11/38, 29%) refused surgery and were treated solely with chemoradiation despite having a good (ECOG 0-1) functional status. Given the significant survival advantage in patients who received surgery, it seems prudent to be aggressive in offering surgery to patients early and highlighting the survival benefits clearly as well as identifying and eliminating potential socioeconomic barriers.

###### Patients with Potentially Resectable Cancer: Reasons for Not Receiving Surgery

ECOG: Eastern Cooperative Oncology Group

  ------------------------------------------------------------------------ ------ ----------
  Reason                                                                   n=38   \% (/38)
  Tumors not amenable to surgery due to local invasion after neoadjuvant   6      16%
  Tumor too locally advanced at diagnosis                                  3      8%
  Later found to have metastases and plans for surgery were aborted        3      8%
  Lost to follow-up                                                        8      21%
  Refused surgery/treated with chemoradiation despite good ECOG            11     29%
  Poor performance status                                                  4      11%
  Previous gastrointestinal surgery that precluded esophagectomy           3      8%
  ------------------------------------------------------------------------ ------ ----------

Although randomized prospective trials are lacking, the use of endoscopic methods instead of surgery for the treatment of early mucosal esophageal cancer have become ubiquitous, with EMR for T1a the most common approach in the United States and increasing in frequency for T1b tumors \[[@REF13]\]. Observational studies have demonstrated equal survival rate at one, three, and five years for patients with T1a treated with either endoscopic resection or esophagectomy, although endoscopic therapy is associated with a slightly higher recurrence rate \[[@REF14]\]. Similarly, when comparing patients with Stage I cancer who received endoscopic treatment vs. surgery in our study, there was no statistically significant difference in survival noted although this may have been secondary to the limited population size of this subgroup.

Several population-based studies have reported a poorer survival of black patients compared to whites \[[@REF15]-[@REF17]\]. In earlier studies, this was sometimes proposed to be secondary to the increased incidence of SCC (which has poorer survival) in blacks.

However, several epidemiological studies have demonstrated that there may be other factors at play. One study demonstrated worse five-year survival rates for blacks compared to whites (37% vs. 60%, p\<0.001). However, on a multivariate analysis and controlling for histology among other factors, the relationship between race and survival was not significant when surgery was taken into consideration \[[@REF15]\]. Similarly, a subsequent large analysis of the surveillance, epidemiology, and end results (SEER) database confirmed the disparity in survival and incidence in SCC between black and white patients. However, on a multivariate analysis, the survival disparity disappeared after adjusting for the receipt of esophagectomy \[[@REF16]\]. 

Conversely, in a recent study, Taoili et al. confirmed that blacks had a lower rate of esophagectomy; however, the differences in survival persisted even when adjusting for cancer-directed surgery. Interestingly, independent of stage, white and black patients who did not have surgery experienced similar survival, although among patients who did undergo surgery, there was still a poorer overall survival for blacks compared to whites \[[@REF17]\]. Possible explanations for this disparity in esophagectomy rates among blacks may be poorer health care delivery, less access to specialized surgeons, poor access to high-volume centers, or secondary to patient refusal. It is also possible that a proportion of these cancers may be less resectable due to the preponderance of SCC in these patients, and thus the location of cancers in the mid-esophagus \[[@REF15]-[@REF18]\].

In our study, there was a significant difference in survival between white and black patients with potentially resectable cancers (Stage I-III), with whites surviving twice as long as blacks (median survival 538 ± 202 vs. 253 ± 46 days, p=0.03, 95% CI 269-603). When comparing overall survival rates between histology groups, we noted differences in survival, with AC patients having superior survival than SCC patients (303 ± 48 days vs. 233 ± 24, 95% CI 197-339, p=0.01). AC has been shown to have superior survival to SCC in the literature \[[@REF19]-[@REF20]\]. In one study that evaluated survival between AC and SCC patients who underwent curative resection, the five-year survival rate was 42.3% vs, 30.3%, p\<0.01. This disparity in survival was consistent even in patients who had a complete macroscopic and microscopic resection as well as negative lymph nodes (R0N0) \[[@REF21]\]. This poorer survival may be secondary to the higher rate of occult micro-metastases \[[@REF21]\], the histology-specific aggressiveness of cancer, or other confounding factors and exposure relating to the patient population, including race.

In our study, almost 80% of blacks presented with SCC compared with 20% of whites (p\<0.0001). The higher incidence of SCC in blacks compared to whites has been documented in large population studies \[[@REF7]\], but the causes are not fully apparent. Proposed etiologies have involved the lower socioeconomic class (SEC), lower intake of fruits and vegetables, and increased rates of alcohol and tobacco usage \[[@REF22]-[@REF23]\]. However, it is not clear why these factors, while definite risk factors for SCC, result in a higher incidence of SCC in blacks compared with whites. It may be secondary to increased amounts of tobacco and alcohol consumed compared to whites, something hard to accurately quantify in large studies. Furthermore, while lower SEC has been reported to be a risk factor in many studies \[[@REF22],[@REF24]-[@REF25]\], it is not exactly clear what the underlying exposures causing these associations are, as low SEC can be considered a surrogate for various lifestyle and environmental exposures, including poor nutrition, poor access to health care, and poor housing \[[@REF22]\].

Underlying genetic polymorphisms and race-specific genetic susceptibility may prove to play a significant role in the pathogenesis of SCC. Many recent studies have found various single nucleotide polymorphisms (SNPs) in micro RNA (miRNA) sequences in SCC patients compared with controls \[[@REF26]-[@REF27]\]. These mutations, under the potential effects of factors like alcohol and tobacco, may lead to an alteration of miRNA expression and contribute to carcinogenesis.

Others have reported polymorphic mutations in genes coding for metabolic enzymes, Deoxyribonucleic acid (DNA) repair enzymes and cytokines, which may contribute toward SCC susceptibility \[[@REF28]-[@REF30]\]. While the majority of these studies were done investigating the particularly high incidence of SCC in China and the so-called "esophageal cancer belt," it may help to explain the increased incidence of SCC in blacks compared to whites.

This study benefits from several strengths. To our knowledge, this is the only cohort of esophageal cancer patients in the United States where such detailed variables, such as potential risk factors and symptoms at presentation, were included, in addition to various laboratory clinical and pathological data across all stages and treatment modalities. In addition, this study's detailed survival analysis presented in days and stratified by various variables gives providers a better idea of realistic median survival as compared to the five-year survival rates presented elsewhere in the literature. All patients in this cohort were veterans and the VA North Texas Health Care System (VANTHCS) was their primary hospital. All follow-up and treatment were conducted there. This fact, along with the comprehensive and centralized computerized health records, allowed us to collect accurate data endpoints and calculate reliable survival times.

There were a few weaknesses in this study. First, the cohort was of a relatively small sample size and the findings must be interpreted in light of the inherent bias in a retrospective study with a sample of this size. Our population was predominantly male, and of white or black race, and findings cannot be generalizable to other races or women. In addition, it is possible that our patient population had a higher incidence of baseline risks factors (e.g. smoking), which may affect our findings and make them not generalizable to other patient populations.

Conclusions
===========

In conclusion, there was a significant difference in survival between AC and SCC patients and between White and Black patients with resectable cancer. However, histology and race did not play a role in survival when other factors were controlled in a multivariate analysis. Surgery was found to be an independent predictor of mortality. Given the improved survival benefit of surgery as well as its underuse, clinicians should be more aggressive in offering potentially curative esophagectomies to patients.
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